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Summary Background An association between hepatitis C virus (HCV) infection and lichen planus (LP) has
been investigated, but results have been inconsistent.
Objectives To investigate the relationship between LP and HCV seropositivity.
Methods In a cross-sectional study we tested the sera of 303 consecutive newly diagnosed patients
with histologically proven LP referred to three Italian centres for the presence of anti-HCV IgG.
A comparable control group was also tested. Next, in a systematic review, studies were identified by
searching different databases in April 2004. Inclusion criteria were: (i) analytical study design;
(ii) clinical and histological diagnosis of LP; and (iii) serological test for anti-HCV antibodies as main
outcome. The risk of bias was assessed on the basis of characteristics of the study group, appro-
priateness of the control group and study design. Pooled data were analysed by calculating odds
ratios (ORs), using a random effects model.
Results In the cross-sectional study, nearly one in five (19Æ1%) of the LP group was HCV positive,
while a much lower prevalence of infection was found in the control group (3Æ2%) [OR 7Æ08; 95%
confidence interval (CI) 3Æ43–14Æ58]. The systematic review yielded 25 relevant studies, six of
which had a low risk of bias. There was a statistically significant difference in the proportion of
HCV-seropositive subjects among patients with LP, compared with controls (OR 4Æ80; 95% CI 3Æ25–
7Æ09). Following subgroup analyses, the variability of HCV prevalence in patients with LP seemed to
depend on geographical area, but not on age.
Conclusions Anti-HCV circulating antibodies are more common in patients with LP than in con-
trols, although such an association may not be significant in some geographical areas.
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Lichen planus (LP) is a mucocutaneous disease of
chronic inflammatory nature, commonly seen in der-
matological and dental clinics. Although many aspects
of the pathogenesis of LP have recently been clarified,1
no aetiological agent has been identified so far. LP has
been described in association with numerous systemic
conditions, including immunologically mediated dis-
eases, infections and malignancies, but the evidence has
been equivocal.2 In the last 15 years an increasingly
strong association between LP and chronic hepatic
disease has been suggested.3 Since the first report of a
patient with LP who was infected with hepatitis C virus
(HCV),4 an RNA virus identified in 19895 and currently
considered a leading cause of chronic liver disease, the
link between LP and this virus has been the subject of
numerous reports investigating the prevalence of HCV
infection in groups of patients with LP. Unfortunately,
the results of such reports are not consistent, varying
from 06 to > 60%.7
We aimed: (i) to investigate the prevalence of HCV
seropositivity in a large group of patients with oral LP
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in three Italian cities, and to compare it with a specially
selected control group; and (ii) to analyse the currently
available evidence to test the null hypothesis that there
is no difference between the proportion ⁄ number of




This multicentre cross-sectional study included data
from three Italian cities, two from the north (Milan
and Brescia) and one from the centre of the country
(Rome). The case groups were formed by consecu-
tive patients with a clinical and histological diagno-
sis of oral LP, attending the Oral Medicine clinics of
three university dental schools. Control groups
comprised patients without known hepatic diseases,
attending the clinics of the three dental schools for
reasons other than oral mucosal diseases. The sera
of all the subjects were tested for the presence of
anti-HCV IgG by means of a third-generation
enzyme-linked immunosorbent assay (ELISA) (Vitros
ECi Immunodiagnostic System; Ortho-Clinical Diag-
nostics, Raritan, NJ, U.S.A.), according to the
manufacturer’s instructions. Positive results were
confirmed by a line immunoassay (Inno-Lia HCV
Ab III Update). Odds ratios (ORs) and 95% confid-
ence intervals (CIs) were calculated for each group
and for the total of the subjects enrolled in the three
cities.
Systematic review
Studies addressing the relationship between LP and
HCV seropositivity were included in the present
systematic review when they fulfilled the following
criteria: (i) analytical study design as indicated by
Grimes and Schulz,8 i.e. an observational study with a
comparison or control group; (ii) clinical and histolog-
ical diagnosis of LP; and (iii) serological test for
circulating anti-HCV antibodies as main outcome. To
identify relevant literature, we searched MEDLINE,
EMBASE and LILACS databases in April 2004 using the
following terms: ‘Hepatitis C’, ‘Hepacivirus’, ‘HCV’,
‘lichen planus’ and ‘lichen*’. To identify additional
studies, references lists of previously identified pub-
lished papers were searched and the world wide web
was searched by means of a search engine (http://
www.google.com). The title and abstract of each article
resulting from the literature search were examined and
when the article was considered relevant, the full
report was obtained.
Every study included was assessed by one reviewer
(G.L.) on the basis of: (i) characteristics of the study
group (consecutive, unselected patients with LP);
(ii) appropriateness of the control group: subjects
belonging to the control group must not differ import-
antly from those of the study group, apart from the
diagnosis of LP (sex and age must be matched, subjects
of the control group must be selected from the study
base); and (iii) prospective design (i.e. data and sera
collected on purpose). Each of these criteria was rated
as met, unmet or unclear. The global validity of the
study was assessed using three categories: (i) low risk of
bias: all criteria met; (ii) moderate risk of bias: one or
two criteria unclear; and (iii) high risk of bias: at least
one criterion unmet or three criteria unclear. The
critical appraisal of the studies was carried out without
blinding the name of the authors, institutions or
journal. Data about the study, its eligibility, validity,
design and outcome information, were recorded on an
abstraction form.
For each study, data were extracted on the
numbers of patients with LP and controls who were
anti-HCV positive, and on the total numbers of
patients and controls. For each study an OR and
95% CI was calculated. Where absence of events
(seropositive patients) in one of the groups caused
problems with computation of OR, 0Æ5 was added to
all values for that study, except when absence of
events involved both study and control groups, in
which case OR was undefined.9 As heterogeneity
among studies was expected on the basis of a large
variability in HCV prevalence across different coun-
tries, a random effect was used to calculate the
summary estimate.
Subgroup analysis was undertaken for geographical
area, patients with oral lesions, age, and origin of the
control group. Sensitivity analysis was undertaken
(i) excluding studies of lower methodological quality
(i.e. studies at high risk of bias) and (ii) excluding
data from the present multicentre study. To investi-
gate potential for publication bias we checked for
asymmetry of the funnel plot of the OR of the
included studies. The statistical analysis was conduc-
ted using Rev Man Analyses 1, the statistical package
of Review Manager 4.2, a copyrighted freeware
developed by the Cochrane Collaboration, for preparing
and maintaining reviews (http://www.cochrane-net.
org/revman).
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Results
Cross-sectional study
At the end of the study the case group was formed by
303 patients (211 women, 92 men; mean age
61Æ2 years, range 28–88) with a clinical and histolog-
ical diagnosis of oral LP; 85 patients had an atrophic or
erosive variant of the oral disease, while the remaining
218 patients had a reticular or plaque form. Skin
lesions compatible with cutaneous LP were detected in
just 11 patients. The control group comprised 278
subjects (159 women, 119 men; mean age 61Æ4 years,
range 33–85). Fifty-eight subjects (19Æ1%) of the case
group were HCV seropositive in a third-generation anti-
HCV ELISA test compared with nine of the control
group (3Æ2%). The difference between the prevalence of
HCV seropositivity in the two groups was statistically
significant (OR 7Æ08; 95% CI 3Æ43–14Æ58). The results
for the three centres are shown in Table 1.
Systematic review
Characteristics of the studies. From 416 articles identi-
fied by the different search strategies, 42 potentially
eligible studies were identified (Fig. 1). Of these, 16
were excluded because they had no control group
(descriptive design), one was excluded for including
patients without histological diagnosis10 and one was
excluded11 for reporting data published in a previous
article.12 Results of the current cross-sectional study
were also included. The main characteristics of the 25
studies included are presented in Table 2.12–35 Seven-
teen of the 25 studies were from European countries,
two from the U.S.A., two from Africa, three from Asia
and one from South America. Two studies were written
in a language other than English: one in Portuguese13
and one in Italian.19
Eight studies included only patients with oral lesions,
which were present in a variable proportion in most of
the other studies. The control group was enrolled
among dermatological patients in 13 studies: in one
case some patients with potentially HCV-associated
dermatological conditions (porphyria cutanea tarda,
cutaneous vasculitis and prurigo) were excluded,30
while another included psoriasis patients only.35 The
other control groups comprised dental patients (three
studies), surgical patients (two studies), healthy sub-
jects (two studies), dental healthcare workers (two
studies), blood donors (one study) and patients with
unrelated oral keratoses (one study); in two studies
the origin of the control group was not specified. One
study included two control groups.12 The serological
test adopted to detect circulating anti-HCV antibodies
was a second-generation ELISA in 13 studies and a
Table 1. Characteristics and hepatitis C virus (HCV) prevalence in three groups of Italian patients














Milan 98 ⁄ 46 61Æ7; 28–88 30 ⁄ 144 (20Æ8%) 58 ⁄ 38 62Æ4; 33–82 4 ⁄ 96 (4Æ2%) 6Æ05 (2Æ05–17Æ80)
Brescia 58 ⁄ 19 59Æ8; 28–79 19 ⁄ 77 (24Æ7%) 46 ⁄ 54 61Æ2; 32–75 3 ⁄ 100 (3Æ0%) 10Æ59 (3Æ00–37Æ35)
Rome 55 ⁄ 27 61Æ8; 34–87 9 ⁄ 82 (11Æ0%) 55 ⁄ 27 60Æ4; 39–85 2 ⁄ 82 (2Æ4%) 4Æ93 (1Æ03–23Æ58)
Total 211 ⁄ 92 61Æ2; 28–88 58 ⁄ 303 (19Æ1%) 159 ⁄ 119 61Æ4; 32–85 9 ⁄ 278 (3Æ2%) 7Æ08 (3Æ43–14Æ58)
OR, odds ratio; CI, confidence interval.
Reports identified searching the three databases 
MEDLINE =   209    (April 2004) 
EMBASE =    198    (April 2004) 
LILACS =  8 (April 2004) 
Other =  1 (April 2004) 
Studies = 416 
Studies = 42 
Studies = 26 
Studies = 24
Studies included in the 
systematic review = 25 
374 studies were excluded because not relevant 
16 studies were excluded because of the descriptive design 
(i.e. without control group)
1 study was excluded for including patients without histological diagnosis 
and 1 for including previously published data
original data from the present study were included 
Figure 1. Flow diagram.
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third-generation ELISA in eight; in four cases the char-
acteristics of the test were not reported. Positive results
were confirmed by means of another test in 13 studies.
Critical appraisal of the included studies. On the basis of
the criteria previously described, six studies were
judged to be at low risk of bias, 10 at moderate risk,
and nine at high risk of bias (Table 3). The first
criterion was met in about one third of the studies, as
the study group was clearly formed by consecutive,
unselected patients with LP in only 10 of the 25
studies. Of the other two criteria, the control group was
adequately selected and matched in 15 cases and the
study had a prospective design in 14. None of the
studies published in the form of letter or abstract was
judged to be at low risk of bias.
Data analysis. The total number of subjects in the
included studies was 4057. One of the studies was
considered twice in the meta-analysis because the
authors included two control groups, with different
characteristics, giving opposing results when compared
with the study group.12 This solution was judged to be
better (more conservative) than the possible alterna-
tives (to combine the two control groups or to choose
just one of them). In three studies no seropositive
patients were found in either group.22,29,32 In these
studies the OR could not be calculated. The proportion
of HCV-positive subjects was higher in the LP group
compared with controls in all but two of the other
studies, the OR for HCV seropositivity in patients with
LP varying between 0Æ23 (95% CI 0Æ01–5Æ85)33 and
15Æ94 (95% CI 2Æ00–127Æ22).23
The summary estimate OR for all studies was 4Æ80
(95% CI 3Æ25–7Æ09) (Fig. 2), showing a statistically
significant difference in the proportion of HCV-seropos-
itive subjects among patients with LP, compared with
controls. As would be expected, the heterogeneity test
showed statistically significant heterogeneity (P ¼
0Æ04).




Lichen planus group Control group Serological tests
n
Patients with
oral lesions n Provenance Screening Confirmatory
Brazil Issa 199913 34 9 ⁄ 34 60 Blood donors ELISA 3 Unspecified
France Cribier 199414 52 4 ⁄ 52 112 Dermatology patients ELISA 2 RIBA 2
Dupin 199715 102 102 ⁄ 102 306 Surgical patientsa ELISA 3 RIBA 3
Egypt Ibrahim 199916 43 Unspecified 30 Dermatology patients Unspecified Unspecified
Germany Imhof 199717 84 45 ⁄ 84 87 Dermatology patients ELISA 2 RIBA 2
Italy Carrozzo 199618 70 70 ⁄ 70 70 Patients with unrelated
oral keratosesb
ELISA 2 RIBA 2
Serpico 199719 100 100 ⁄ 100 100 Dental patients ELISA 2 RIBA 2
Mignogna 199820 263 263 ⁄ 263 100 Dental patients ELISA 2 RIBA 2
Lodi 2004 (present data) 303 303 ⁄ 303 278 Dental patients ELISA 3 Line immunoassay
Japan Tanei 199521 45 37 ⁄ 45 45 Surgical patients (orthopaedic) ELISA 2 Unspecified
Nepal Garg 200222 86 29 ⁄ 86 43 Unknown ELISA 3 –d
Nigeria Daramola 2002a12 57 Unspecified 24 Healthy subjects ELISA 2 Unspecified
Daramola 2002b12 57 Unspecified 24 Dermatology patients ELISA 2 Unspecified
Spain Santander 199423 50 Unspecified 27 Dermatology patients ELISA 2 PCR
Gimenez-Arnau 199524 25 Unspecified 18 Unknown Unspecified Unspecified
Sanchez-Perez 199625 78 56 ⁄ 78 82 Dermatology patients ELISA 2 Unspecified
Bagan 199826 100 100 ⁄ 100 100 Healthy subjects ELISA 2 RIBA 2 or 3
Gimenez-Garcia 200327 101 53 ⁄ 101 99 Dermatology patients ELISA 2 RIBA 2
Thailand Klanrit 200328 60 60 ⁄ 60 60 Dental healthcare workers ELISA 3 RNA
Turkey Ilter 199829 75 Unspecified 75 Dermatology patients Unspecified –d
Kirtak 200030 73 27 ⁄ 73 73 Dermatology patientsc ELISA 3 Unspecified
Erkek 200131 52 7 ⁄ 52 54 Dermatology patients ELISA 3 Unspecified
U.K. Ingafou 199832 55 55 ⁄ 55 110 Dental healthcare workers ELISA 3 –d
Tucker 199933 45 13 ⁄ 45 32 Dermatology patients ELISA 2 RIBA 3
U.S.A. Bellman 199534 30 Unspecified 41 Dermatology patients ELISA 2 RIBA 2
Beaird 200135 24 Unspecified 20 Dermatology patients (psoriasis) Unspecified Unspecified
ELISA, enzyme-linked immunosorbent assay; RIBA, recombinant immunoblot assay (2, second generation; 3, third generation); PCR, polymerase
chain reaction. aExcluding patients with hepatic diseases, receiving haemodialysis and transplant patients. bLeucoplakia, frictional keratosis,
verrucous carcinoma, nicotinic stomatitis, white sponge naevus. cExcluding patients with porphyria cutanea tarda, cutaneous vasculitis and
prurigo. dAll subjects were negative.
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Subgroup analysis. As illustrated in Figure 3, eight
studies included only patients with oral LP (with and
without cutaneous lesions). The summary estimate OR
for these studies (5Æ71; 95% CI 3Æ48–9Æ37) was not
substantially different from the global one. When the
studies from two geographical areas (Northern Europe
and Mediterranean basin) were analysed separately,
the heterogeneity test showed a good homogeneity
in the two subgroups (P ¼ 0Æ11 and P ¼ 0Æ88,
respectively). The summary estimate OR increased
considerably in the Mediterranean studies (6Æ63; 95%
CI 4Æ68–9Æ40), but halved in the studies from Northern
Europe, becoming nonsignificant (2Æ14; 95% CI 0Æ59–
7Æ69). The pooled data from studies with a study group
with a mean age of £50 years showed that even in LP
groups of younger age, the frequency of HCV seropo-
sitivity was significantly higher than in control groups
(OR 3Æ62; 95% CI 1Æ73–7Æ60). When characteristics of
the control groups were considered, the association of
LP and HCV seropositivity was confirmed for studies
enrolling controls among dermatological patients (OR
4Æ72; 95% CI 2Æ76–8Æ05) or dental and surgical
patients (OR 5Æ95; 95% CI 3Æ39–10Æ44). In studies
with healthy subjects or blood donors as controls, the
OR, although higher than 1, was not significant (OR
2Æ16; 95% CI 0Æ39–11Æ88).
Sensitivity test. As shown in Figure 4, when studies
with high risk of bias were excluded from the meta-
analysis the summary estimate OR did not change
substantially (4Æ08; 95% CI 2Æ54–6Æ55). All the ana-
lyses were also repeated excluding the data from the
present study, without producing significant changes
in the summary estimates (data not shown). Visual
examination of the symmetry of the funnel plot did not
suggest a large publication bias.
Discussion
HCV infection is a global health problem: 170 million
persons may be infected worldwide,36 and the propor-
tion of HCV-positive individuals varies from < 1% in
Northern European countries to > 15% in Egypt.37 The
prevalence data for the countries represented in the
studies included in the systematic review are summar-
ized in Table 4.
One of the prominent aspects of HCV infection is the
frequent presence of putative extrahepatic mani-
festations. For some of these, namely mixed
cryoglobulinaemia38 and membranoproliferative
glomerulonephritis,39 the association with HCV infec-
tion is now well established, while for others it is still
under debate. This is the case for LP, a relatively common
condition whose association with chronic hepatic dis-
ease was described years before identification of HCV.3
The present cross-sectional study and systematic
review seem to confirm the association between LP and
the presence of circulating anti-HCV antibodies. This
does not strictly equate with HCV infection, although
the high rate of chronicity of the infection (75%) would
suggest that most seropositive patients are also infec-
ted, as shown by the few studies where serum RNA was
used as a confirmatory test.17,18,23,25,28,31,34
The results of this multicentre cross-sectional
study, the largest of its kind, demonstrate that HCV
immunoglobulins are a common finding in the sera
of Italian patients with LP, independent of the
geographical area. HCV seroprevalence in the three
study groups ranged between 11% and 24Æ7%. This
variability is possibly due to chance or to differences
in group size, or may be due to differences in
seroprevalence in the study population, although in
this case larger differences among control group
prevalences would be expected.












Carrozzo 199618 Met Met Met Low
Erkek 200131 Met Met Met Low
Gimenez-Garcia 200327 Met Met Met Low
Lodi 2004 Met Met Met Low
Sanchez-Perez 199625 Met Met Met Low
Tucker 199933 Met Met Met Low
Bagan 199826 Unclear Met Unclear Moderate
Bellman 199534b Unclear Met Unclear Moderate
Cribier 199414 Met Unclear Met Moderate
Daramola 200212 Unclear Met Met Moderate
Dupin 199715 Unclear Met Met Moderate
Garg 200222 Met Unclear Met Moderate
Ilter 199829b Unclear Met Met Moderate
Kirtak 200030 Unclear Met Unclear Moderate
Serpico 199719 Unclear Met Unclear Moderate
Tanei 199521 Unclear Met Met Moderate
Beaird 200135b Unmet Unclear Unmet High
Gimenez-Arnau 199524a Unclear Unclear Unclear High
Ibrahim 199916 Met Unmet Met High
Imhof 199717 Met Met Unmet High
Ingafou 199832 Unclear Unmet Unclear High
Issa 199913 Unclear Unmet Unclear High
Klanrit 200328 Unclear Unmet Met High
Mignogna 199820 Unclear Unclear Unclear High
Santander 199423a Unclear Unclear Unclear High
aAbstract. bLetter.
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The results of the present cross-sectional study are
consistent with those of the previous controlled
studies included in the systematic review. In all but
two of these studies the proportion of HCV-seropos-
itive subjects was higher among patients with LP
than among controls, and this difference was statis-
tically significant in 11 of 26 comparisons (one study
had two comparisons). The summary estimate OR for
all included studies was 4Æ80 (95% CI 3Æ25–7Æ09),
indicating a higher risk for patients with LP to be
HCV seropositive, compared with subjects without
LP, in other words indicating an association between
the two conditions.
The heterogeneity found among the studies was
expected because of the highly variable prevalence of
HCV infection across the world. For this reason a
random effect model was adopted. The variability of
HCV infection prevalence as source of heterogeneity
was in part confirmed when subgroup analysis by
geographical area was undertaken, resulting in a
marked reduction of heterogeneity.
The overall quality of the included studies was
relatively satisfactory: only nine of 25 studies were
judged at high risk of bias. The composition of the study
group was the most critical criterion, being met in only
10 of 25 studies. It must be emphasized that critical
appraisal of observational studies is particularly diffi-
cult because of the many potential sources of errors
and bias that are virtually impossible to control and
assess fully.
Publication bias is considered another central issue
in systematic reviews of observational studies.40 For
this reason, our search strategy included not only the
usual biomedical databases but also non-English
sources and the world wide web, where we found
useful studies not included elsewhere. In addition,
visual examination of the funnel plot did not suggest
gross publication bias.
The association between HCV infection and LP has
been questioned. A high prevalence of HCV infection
in the general population, especially in subjects
aged > 50 years, has been indicated as a possible
confounding factor in studies investigating the rela-
tionship between HCV and LP. The hypothesis is that,
as most patients with LP are aged > 50 years, the high
frequency of HCV seropositivity found in LP groups is
just the normal prevalence for the corresponding age
group. The results of the present review seem to
confute such a hypothesis. In 16 of the 25 included
studies, the control group was sex- and age-matched
Figure 2. Forest plot of odds ratio (OR) of hepatitis C virus seropositivity [and 95% confidence interval (CI)] in patients with lichen planus.
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with the study group and thus the difference in HCV
seroprevalence between the two cannot be ascribed to
age of the patients with LP. In addition, the subgroup
analysis of studies with LP patients £50 years also
showed an association between HCV infection and LP
in these cases. Furthermore, the studies from the
countries with the highest HCV prevalence in the
general population (Egypt and Thailand) showed a
Figure 3. Subgroup analysis. (a) Patients with oral lesions, geographical area and patients aged £ 50 years. (b) Control group selection. OR, odds
ratio; CI, confidence interval.
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negative or nonsignificant association, showing that
high prevalence in the general population and in
specific age groups cannot completely explain the LP–
HCV association.
Controlled studies investigating LP frequency in HCV-
infected patients are few and with relatively small study
groups:26,41,42 they reported a prevalence of LP of about
4%, although estimates from uncontrolled studies range
from about 1%43 to 20%.44 A recent case–control study
showed a significant twofold increase in LP prevalence
among 34 204 HCV-positive subjects compared with
136 816 controls.45 Notably, the members of the study
group were significantly younger than those in the
control group (45Æ2 vs. 56Æ9 years).
Although an association between LP and HCV
seems to be confirmed by the evidence presented in
this work, caution is needed in inferring a causative
role for HCV infection in the aetiopathogenesis of LP.
However, some studies have investigated the putative
pathological basis for such a hypothesis: HCV anti-
gens and RNA46,47 have been found in LP tissue by
some authors, although negative results have also
been reported,48 and HCV-specific T cells have
recently been demonstrated in oral mucosa affected
by LP.49
We conclude that it seems reasonable to test the sera
of patients affected by LP for anti-HCV antibodies, as
suggested by other authors,18 and that the reasons
underlying such an association need to be better
investigated by both epidemiological studies and basic
scientific experiments.
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